Smith & Nephew : Q4 review – Solid finish to 2023, guidance well reflected
>Q4 review – Solid finish, in line with expectations - Q4 2023 revenues of $ 1,458m (+9.0% y-o-y) were 2% ahead of ODDO BHF/consensus expectations. Underlying growth was 6.4% (vs 6.0%/5.3% expected). Forex tailwind accounted for 40bp. FY trading profit reached $ 970m (+7.7% y-o-y/margin 17.5%), in line with our forecast and consensus. Adjusted EPS of $ 0.83 was +1%/2% vs expectations.Segmental view – Advanced wound management with strongest growth - I...Smith & Nephew is a global medical devices business operating in the markets for advanced surgical devices comprising orthopaedic reconstruction and trauma, sports medicine and advanced wound management. Co.'s advanced medical products and services include: Orthopaedic Reconstruction and Trauma (joint replacement systems for knees and hips and products to help repair broken bones); Advanced Wound Management (treatment and prevention products for hard-to-heal wounds); and Sports Medicine (implants and enabling technologies for minimally invasive repair of the joint).
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.